Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Follitropin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Anixa Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
Details : Follicle Stimulating Hormone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
April 07, 2022
Lead Product(s) : Follitropin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Anixa Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable